Display Settings:

Format

Send to:

Choose Destination
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
    J Clin Psychiatry. 2007;68 Suppl 8:35-41.

    Revisiting monoamine oxidase inhibitors.

    Source

    Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC 27710, USA.

    Abstract

    Monoamine oxidase inhibitors (MAOIs) were among the first class of agents introduced for the treatment of depression. However, they have fallen out of favor among clinicians over the years, due mostly to an unfavorable safety profile, the need for restrictive dietary prohibitions, and the fear of hypertensive crisis. The development of a novel, transdermal MAOI system now offers clinicians an additional option for managing patients with unipolar, bipolar, atypical, and treatment-resistant depression.

    PMID:
    17640156
    [PubMed - indexed for MEDLINE]

      Supplemental Content

      Icon for Allen Press, Inc.

      Save items

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk